BeOne Medicines (BEIGF) Income from Non-Controlling Interests (2017 - 2020)
BeOne Medicines (BEIGF) reported Income from Non-Controlling Interests of $96000.0 for Q4 2020, down 42.17% year-over-year from $166000.0 in Q1 2020, and up 106.89% quarter-over-quarter from -$1.4 million in Q3 2020.
BeOne Medicines (BEIGF) Income from Non-Controlling Interests (2017 - 2020) Analysis & Trends
BeOne Medicines (BEIGF) has 4 years of Income from Non-Controlling Interests data on file, last reported at $96000.0 in Q4 2020.
- Income from Non-Controlling Interests for Q4 2020 came in at $96000.0, down 42.17% year-over-year; the trailing twelve-month figure through Sep 2021 was $96000.0 (up 102.71% YoY), and the FY2020 annual result was -$3.6 million, down 85.49% from the prior year.
- Income from Non-Controlling Interests improved to $96000.0 in Q4 2020 per BEIGF's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $1.5 million in Q4 2018 and troughed at -$1.4 million in Q3 2020.
- A 4-year average of -$401666.7 and a median of -$429000.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 3493.02% in 2018 and fell as far as 513.33% in 2018.
- A 4-year view of Income from Non-Controlling Interests shows it stood at $43000.0 in 2017, then surged by 3493.02% to $1.5 million in 2018, then slumped by 89.26% to $166000.0 in 2019, then sank by 42.17% to $96000.0 in 2020.
- Business Quant data shows BEIGF's Income from Non-Controlling Interests at $96000.0 in Q4 2020, -$1.4 million in Q3 2020, and -$1.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | BeOne Medicines | - | - | 1.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 96,000.00 |
| Sep 30, 2020 | -1.39 Mn |
| Jun 30, 2020 | -1.12 Mn |
| Mar 31, 2020 | -1.20 Mn |
| Dec 31, 2019 | 166,000.00 |
| Sep 30, 2019 | -1.30 Mn |
| Jun 30, 2019 | -384,000.00 |
| Mar 31, 2019 | -429,000.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | -461,000.00 |
| Jun 30, 2018 | -828,000.00 |
| Mar 31, 2018 | -520,000.00 |
| Dec 31, 2017 | 43,000.00 |
| Sep 30, 2017 | -102,000.00 |
| Jun 30, 2017 | -135,000.00 |